Systemic Lupus Erythematosus and Lupus Nephritis Drugs Market by Drug Class (Antimalarials, Biologics, Immunosuppressives, Steroids) and Forecast 2017-2021

Systemic Lupus Erythematosus and Lupus Nephritis Drugs Market by Drug Class (Antimalarials, Biologics, Immunosuppressives, Steroids) and Forecast 2017-2021

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by systemic chronic inflammation that can affect multiple major organ systems. A major contributor to morbidity and mortality among patients with SLE is renal involvement, known as lupus nephritis (LN). Treatment of systemic lupus erythematosus is guided by the individual patient’s manifestations. Fever, rash, musculoskeletal manifestations, and serositis generally respond to treatment with hydroxychloroquine, nonsteroidal anti-inflammatory drugs (NSAIDS), and steroids in low to moderate doses, as necessary, for acute flares. Medications such as methotrexate may be useful in chronic lupus arthritis, and azathioprine and mycophenolate have been widely used in lupus of moderate severity. The treatment options for LN include acetaminophen or NSAIDs. Acetaminophen and NSAIDS are often enough to reduce symptoms, but sometimes are prescribed in combination with antimalarial drugs such as hydroxychloroquine (Plaquenil). Low-dose corticosteroids such as prednisone and/or corticosteroid creams or ointments. Central nervous system involvement and renal disease constitute more serious disease and often require high-dose steroids and other immunosuppressive agents, such as azathioprine, belimumab, cyclophosphamide, methotrexate, or mycophenolate mofetil. The LUMINA (Lupus in Minorities: Nature versus Nurture) study and other trials have offered evidence of a decrease in flares and prolonged life in patients given hydroxychloroquine, making it the cornerstone of SLE management.

The global systemic lupus erythematosus and lupus nephritis drugs market segmentation is based on drug class (antimalarials, biologics, immunosuppressives, steroids).

The global systemic lupus erythematosus and lupus nephritis drugs market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global systemic lupus erythematosus and lupus nephritis drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global systemic lupus erythematosus and lupus nephritis drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global systemic lupus erythematosus and lupus nephritis drugs market and profiled in this report include Active Biotech, Anthera, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Galapagos NV, Genentech (Roche), GlaxoSmithKline, Immunomedics, ImmuPharma, Invion, Johnson & Johnson, MedImmune, Merck Serono, Pfizer, SuppreMol, Teva Pharmaceutical Industries Ltd., and UCB (Union Chimique Belge).

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Systemic Lupus Erythematosus and Lupus Nephritis Drugs Market

1. Drug Class
1.1. Antimalarials
1.2. Biologics
1.3. Immunosuppressives
1.4. Steroids

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Active Biotech
3.2. Anthera
3.3. Biogen Idec
3.4. Bristol-Myers Squibb
3.5. Eli Lilly
3.6. Galapagos NV
3.7. Genentech (Roche)
3.8. GlaxoSmithKline
3.9. Immunomedics
3.10. ImmuPharma
3.11. Invion
3.12. Johnson & Johnson
3.13. MedImmune
3.14. Merck Serono
3.15. Pfizer
3.16. SuppreMol
3.17. Teva Pharmaceutical Industries Ltd.
3.18. UCB (Union Chimique Belge)

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*